Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Brentuximab Vedotin for Steroid Refractory GvHD

This study has been completed.
Sponsor:
Collaborators:
Seattle Genetics, Inc.
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Yi-Bin A. Chen, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01596218
First received: May 9, 2012
Last updated: March 21, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)